New drug combo shows promise in early breast cancer trial

NCT ID NCT01597388

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new experimental drug called AZD2014 combined with the standard hormone therapy fulvestrant in 99 people with advanced ER+ breast cancer. The main goals were to check the safety of the combination and find the right dose. Researchers also looked for early signs that the treatment might help shrink tumors or slow the cancer's growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD2014 (an experimental drug) and fulvestrant (a hormone therapy)
What this could lead to: If successful, this could lead to a new combination treatment option for people with advanced ER+ breast cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a very early Phase 1 trial with only 99 participants, focused mainly on safety and dosing. The drug may not prove effective enough to advance to larger studies, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC BREAST CANCER

Contacts and locations

Locations

Research Site

Sarasota, Florida, 34232, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Oklahoma City, Oklahoma, 73104, United States
Research Site

Greenville, South Carolina, 29605, United States
Research Site

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.